Rania Isabella Rodriguez

Ms. Rania Isabella Rodriguez


Research Focus & Metrics

Academic Career Length

1Year (2026-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 October 2026 in Viruses
Verified
Journal Article
Open access
PDF file
ADAmie Donner
Amie Donner
TSTaebin Son
Taebin Son
SBSanjna Boda
Sanjna Boda
CKClaire T. Kenney
Claire T. Kenney
ACAlexis Chiandussi
Alexis Chiandussi
Uri MbonyeUri Mbonye
Uri Mbonye
Recent efforts to employ ectopic Tat as a latency-reversal strategy can benefit from the identification of Tat variants with more efficient transactivation activity. Tat primarily serves as a recruiter of the host transcription elongation factor P-TEFb to proviral HIV to stimulate transcription elongation. Tat can also functionally interact with a host of chromatin-modifying enzymes to promote HIV transcription initiation. In actively dividing T cells, P-TEFb is kept inactive by the 7SK snRNP complex. Although Tat is capable of physically extracting P-TEFb from 7SK snRNP as well as forming an assembly with the sequestrator complex, it is unclear whether Tat:7SK snRNP (Tat:7SK) is a reversible functional intermediate that mediates the recruitment of P-TEFb to proviral HIV. This study explored the reversibility of Tat:7SK and whether Tat clade variants differ in their ability to assemble this complex, mobilize P-TEFb and transactivate latent HIV. While the ectopic expression of clade B NL4-3 Tat caused a substantial dissociation of P-TEFb from 7SK snRNP, affinity tag-based immunoprecipitation experiments confirmed the assembly of Tat:7SK with the displacement of the P-TEFb inhibitory component HEXIM1. The P-TEFb kinase inhibitor flavopiridol (FVP), known to rapidly dissociate P-TEFb from 7SK snRNP, also induced the efficient release of Tat:P-TEFb from Tat:7SK, suggesting that P-TEFb remains a component of this latter complex. While Tat variants representing clades A, B, C and CRF_AE exhibited comparable binding to P-TEFb, clade D Tat showed the least binding. Unlike clades B and CRF_AE, clades A and C Tat associated much more weakly with the core 7SK snRNP subunits MEPCE and LARP7, indicating that their bound P-TEFb is likely liberated. Evaluation of latent HIV reactivation in the Jurkat 2D10 clonal model revealed a rapid loss of Tat transactivation capacity over time across all clades examined, with the most striking disparity observed between Clades A and D. Overall, our findings reveal substantial clade-specific differences in Tat’s ability to liberate P-TEFb from 7SK snRNP and transactivate latent HIV, with the clade A variant displaying the highest potency. Contrary to the prevailing paradigm that Tat:7SK is a “dead-end” complex that is unable to avail P-TEFb for transcriptional control, we show that it is a reversible intermediate from which Tat:P-TEFb can be released en bloc.